Nls Pharmaceutics LTD

Samuel Olivier, a Director at NewcelX Ltd., reported transactions involving the acquisition of common shares and warrants on April 27, 2026.

NLS Pharmaceutics and Kadimastem announced a Hong Kong patent grant for their IsletRx cell-selection technology, expanding global intellectual property protection for their diabetes therapy candidate.

NLS Pharmaceutics Ltd. and Kadimastem Ltd. have extended their merger agreement termination date to October 31, 2025, to address further SEC comments on their Form F-4 registration statement.

NLS Pharmaceutics Ltd. and Kadimastem Ltd. have signed a sixth amendment to their merger agreement, clarifying the timing for calculating the exchange ratio based on pre-shareholder meeting data.

NLS Pharmaceutics Ltd. and Kadimastem Ltd. have agreed to a fifth amendment to their merger agreement, extending the termination date from June 30, 2025, to August 31, 2025, to facilitate the completion of the transaction.

NLS Pharmaceutics' CEO provides a comprehensive update on recent financing, positive clinical developments, and the anticipated merger with Kadimastem, targeting early Q3 2025 completion.

League Jinn Sarl and Julien Ruggieri have filed a Schedule 13D, disclosing beneficial ownership of 25.3% of NewcelX Ltd. common shares, primarily acquired through private placements and a merger.

NewcelX Ltd.'s Chief Scientific Officer and Director, Prof. Michel Revel, has increased his beneficial ownership to 20.2% of the company's common shares following a private placement and merger.

NewcelX Ltd.'s Executive Chairman and CEO, Ronen Twito, has filed a Schedule 13D disclosing beneficial ownership of 6.0% of the company's common shares following the merger of NLS Pharmaceutics and Kadimastem.

Ronald Hafner, Chairman of NLS Pharmaceutics Ltd., has significantly increased his beneficial ownership to 13.2% through a series of equity purchases, warrant acquisitions, debt-to-equity conversions, and a put-call agreement.

League Jinn Sarl and Julien Ruggieri have reported a combined beneficial ownership of 21.6% of NewcelX Ltd.'s common shares.

Clover Wolf Capital and Adi Wolf have jointly reported a 7.5% passive ownership stake in NewcelX Ltd., holding 343,120 common shares.

Biotechnology Value Fund and its affiliates reported a beneficial ownership of 0.6% in NewcelX Ltd. common shares.

Lind Global Fund II LP, along with its affiliates, has filed an amendment to its Schedule 13G, reporting a passive beneficial ownership of 4.9% in NLS Pharmaceuticals Ltd. as of December 31, 2024, indicating a reduction from a previous stake.